Chlorthalidone
/ Chlorthalidone, Chlorthalidone, Clorpres, Combipres, Demi-regroton, Edarbyclor, Hemiclor, Kerledex, Lopressidone, Regroton, Tenoretic, Thalitone (chlorthalidone) is a small molecule pharmaceutical. Chlorthalidone was first approved as Hygroton on 1982-01-01. It is used to treat edema, glomerulonephritis, heart failure, hypertension, and liver cirrhosis amongst others in the USA. The pharmaceutical is active against carbonic anhydrase 7. In addition, it is known to target carbonic anhydrase 14, carbonic anhydrase 1, carbonic anhydrase 12, and carbonic anhydrase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Chlorthalidone, Thalitone (discontinued: Chlorthalidone, Hygroton, Thalitone)
CombinationsAtenolol chlorthalidone, Azilsartan medoxomil chlorthalidone, Edarbyclor, Tenoretic (discontinued: Atenolol chlorthalidone, Clonidine chlorthalidone, Clorpres, Combipres, Demi-regroton, Kerledex, Lopressidone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorthalidone
+
Clonidine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COMBIPRES | Boehringer Ingelheim | N-017503 DISCN | 1982-01-01 | 3 products, RLD |
Hide discontinued
Chlorthalidone
+
Metoprolol tartrate
Chlorthalidone
+
Reserpine
Chlorthalidone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| THALITONE | Casper Pharma | N-019574 RX | 1988-12-20 | 2 products, RLD |
Show 1 discontinued
Betaxolol hydrochloride
+
Chlorthalidone
Atenolol
+
Chlorthalidone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TENORETIC 100 | TWi Pharmaceuticals | N-018760 RX | 1984-06-08 | 1 products, RLD, RS |
| TENORETIC 50 | TWi Pharmaceuticals | N-018760 RX | 1984-06-08 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atenolol and chlorthalidone | ANDA | 2025-09-25 |
| chlorthalidone | ANDA | 2025-10-01 |
| edarbyclor | New Drug Application | 2025-07-23 |
| hemiclor | New Drug Application | 2025-03-27 |
| tenoretic | New Drug Application | 2024-01-31 |
| thalitone | New Drug Application | 2019-12-30 |
Indications
FDA
EMA
Show 17 more
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BA: Sulfonamides, low-ceiling diuretics, plain
— C03BA04: Chlortalidone
— C03BB: Sulfonamides and potassium in combination, low-ceiling diruetics, excluding thiazides
— C03BB04: Chlortalidone and potassium
— C03E: Diuretics and potassium-sparing agents in combination
— C03EA: Low-ceiling diuretics and potassium-sparing agents
— C03EA06: Chlortalidone and potassium-sparing agents
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 7 | 7 | 34 | 18 | 17 | 83 |
| Essential hypertension | D000075222 | — | I10 | 1 | 1 | 16 | 2 | 4 | 24 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 3 | — | 4 | 1 | 8 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 2 | 1 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 2 | 2 | — | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | 1 | — | 3 |
| Cardio-renal syndrome | D059347 | — | — | — | 1 | — | 2 | — | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | 1 | 2 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | — | 2 | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | 1 | 2 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 10 | — | 1 | 13 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 3 | 6 | — | 2 | 10 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 2 | 3 | — | — | 5 |
| Coronary disease | D003327 | — | — | — | — | 2 | — | 2 | 4 |
| Healthy volunteers/patients | — | — | — | 2 | — | 1 | — | — | 3 |
| Hypercholesterolemia | D006937 | — | — | — | — | 2 | — | — | 2 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | 2 | — | — | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nephrolithiasis | D053040 | — | N20.0 | — | 1 | — | — | 1 | 2 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | 1 | — | — | 1 | 2 |
| Hypercalciuria | D053565 | — | R82.994 | — | 1 | — | — | 1 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
| Water intoxication | D014869 | — | — | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular stiffness | D059289 | — | — | — | — | — | — | 2 | 2 |
| Ambulatory blood pressure monitoring | D018660 | — | — | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 1 | 1 |
| Calculi | D002137 | — | — | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 1 | 1 |
| Hypokalemia | D007008 | — | E87.6 | — | — | — | — | 1 | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 1 | 1 |
| Patient participation | D010358 | — | — | — | — | — | — | 1 | 1 |
| Self care | D012648 | — | — | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Chlorthalidone |
| INN | chlortalidone |
| Description | Chlorthalidone is a sulfonamide, a member of isoindoles and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | Thiazide-like diuretic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 77-36-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1055 |
| ChEBI ID | 3654 |
| PubChem CID | 2732 |
| DrugBank | DB00310 |
| UNII ID | Q0MQD1073Q (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA2
CA2
Organism
Homo sapiens
Gene name
CA2
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 2
Protein synonyms
CA-II, CAC, Carbonate dehydratase II, carbonic anhydrase B, Carbonic anhydrase C, Carbonic anhydrase II, carbonic dehydratase, Cyanamide hydratase CA2, epididymis luminal protein 76, epididymis secretory protein Li 282
Uniprot ID
Mouse ortholog
Car2 (12349)
carbonic anhydrase 2 (Q9DCY9)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Chlorthalidone
+
Atenolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Chlorthalidone
+
Azilsartan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Chlorthalidone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Chlorthalidone
+
Clonidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,090 documents
View more details
Safety
Black-box Warning
Black-box warning for: Edarbyclor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,040 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use